Division of Merz GmbH & Co. KGaA
Latest From Ulthera Inc.
Guided Therapy Systems CEO Michael Slayton, PhD, has a history of breaking innovative medical technology, with a primary focus on diagnostic and therapeutic ultrasound applications. He tells In Vivo about the 22-year engineering journey that has led him and the company he founded to the cusp of market launch of a non-invasive tissue regeneration device for musculoskeletal injuries.
Following two years of strong exits from biopharma and medtech investment, New Enterprise Associates raised over $3.1 billion for its 15th fund raising. The new pool of capital consists of $2.8 billion for a traditional venture fund – the fourth consecutive fund to top $2.5 billion – and a $350 million “Opportunity Fund” that will be co-invested with the new and prior fund in late-stage growth equity deals.
New Enterprise Associates registered one of its biggest returns ever when Merz agreed to pay up to $600 million for aesthetics company Ulthera. CEO Matthew Likens and lead investor Justin Klein, MD, discuss specifics about the blockbuster deal.
Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.
Diagnostic Imaging Equipment & Supplies
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Merz GmbH & Co. KGaA
- Senior Management
Matthew E Likens, Pres. & CEO
Gregory D Waller, CFO
Michael T Peterson, VP, R&D
Kenneth Lin, MD, VP, Corp. Dev. & Investor Relations
- Contact Info
Phone: (480) 619-4069
1840 South Stapley Dr.
Mesa, AZ 85204
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.